(Q43040659)

English

High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation

scientific article published on 6 September 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

liver transplantation

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Erika Hörnfeldt

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Henrik Gjertsen

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

6 September 2007

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

40

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

259-265

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Treating hepatitis C infection in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Management of hepatitis C virus in special populations: patient and treatment considerations

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Treatment of HCV recurrence: do the pretransplantation rules apply?

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Antiviral action of ribavirin in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Standardization of hepatitis C virus RNA quantification

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Discrepancy of hepatitis C virus genotypes as determined by phylogenetic analysis of partial NS5 and core sequences

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Histological and virological long-term outcome in patients treated with interferon-alpha2b and ribavirin for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

1 reference

https://api.crossref.org/works/10.1080%2F00365540701633020

21 January 2018

Identifiers

10.1080/00365540701633020

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43040659&oldid=1978318790"